Watch. To. The. End. #SVIN2025 just casually dropped a bombshell: CREST-2 says carotid stenting > CEA + medical management. Yes, you read that right. The data has spoken: ARD 3.2%, RR 2.13, and the p-value didn’t come to play. The plenary hall was purely electric. You could

Thrilled to see our new SVIN practice update highlighted on the main stage at #SVIN2025 by @svinsociety President Dr. Thanh Nguyen! 🙌🧠 So grateful to @oozaidat and all my mentors 🙏.. proud to contribute to this important work. 🚀💙 #Stroke #NeuroIntervention @SVINJournal

Many more to come! Thank you @oozaidat @NguyenThanhMD @samialkasab for your support! @ShailThankiMD @OchsnerHealth

"F1" training program, super supportive group, and really talented people! It's all about lifelong friendships and mentorship. @esamaniego

STROKE NEUROLOGY Open house, this Thursday Nov. 13th at 5 PM CST! @CerebrovascLab @uiowa @esamaniego @IowaNeurology @IowaNeurosurg @Mo_majali91 @samialkasab @WaldoGuerrero82 @geerling_lab #stroke @americanheart @svinsociety @SNISinfo @JNIS_BMJ @icurestroke

TNK/tpa for low NIHSS.. Recent trials made me question, even with a "disabling" deficit.. but this well-written editorial by Dr. Khatri shows the limitations of these trials, and that negative subgroup analyses don't equate to lack of clinical benefit https://t.co/sbzbCvY3R1

Within 6 hours, using CTP to rule out #thrombectomy in otherwise eligible #stroke pts not only harms pts but also worsens cost-effectiveness on the healthcare system.. https://t.co/V0UQ96ovL0

Great analogy 🍪

Thank you to the @UTHoustonStroke for featuring BIORISK ICAS. A great“LASSO” analogy (I will use it with permission 😃)

What a brilliant review (and some great analogies) by @Anveshhh at @UTHoustonStroke Clinical Journal Club reviewing the BIORISK ICAS study by @ShadiYaghi2 and @VarshaMuddasan1 Key takeaway: markers of “downstream” hypoperfusion = higher recurrence

Presented at #AHA25: In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results:

Sharing 10-year findings from the ACST-2 trial at the 39th @ESVSmembership annual meeting, Alison Halliday highlighted that, if successful, both #carotid artery stenting (CAS) and carotid endarterectomy (CEA) “substantially reduce long-term stroke rates” https://t.co/1eGlqbGA81

Excited for this new 7-French Balloon guide catheter "Path BGC is a 7-F guide catheter engineered for trackability, stability, and distal access. It is designed for both transradial and transfemoral approaches" https://t.co/XroAv6828k

Congratulations @ShadiYaghi2 on leading this phenomenal work and having us on board.

Day 1 #WSC2025 @CSC_Stroke

Thank you @oozaidat and the Picasso team for having us. @ShailThankiMD, @OchsnerHealth @NeuroIRdoc @svinsociety

Congrats and thank you to Dr. @ShailThankiMD, Dr. @Mo_majali91, Dr. Alicia Nicklas, and the entire @OchsnerHealth team for enrolling the 126th patient in the #PICASSO trial! 🎉 @oozaidat @samialkasab @NguyenThanhMD #stroke #ClinicalTrial

Optimizing outcomes: the impact of Dual Antiplatelet Therapy in mild ischaemic stroke management! Read The Editorial in #EHJ! #stroke #antiplatelet #therapy #EHJ #cardiotwitter @ESCardio @ESC_Journals https://t.co/EF8D8Bp9f9

https://t.co/5wvY1iNXYv

General anesthesia improved 90-day disability outcomes and increased the rate of successful reperfusion compared with moderate sedation in patients undergoing endovascular thrombectomy for acute ischemic stroke. https://t.co/gDuo2vGxyW